日本人小児におけるオマリズマブの長期安全性、忍容性および有効性

基本情報

NCT ID

NCT01328886

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

38

治験依頼者名

Novartis

概要

The purpose of this extension study is to assess the long-term safety and tolerability of omalizumab as an add-on therapy in Japanese pediatric patients (6 to 15 years of age) with inadequately controlled allergic asthma despite current recommended treatment by providing continued treatment with omalizumab to patients who have previously completed the core study.

対象疾患

介入

依頼者（Sponsor）